The St. Luke's Hospitals--MeritCare CCOP proposes to refine and expand its existing cancer treatment and control research program. The overall goal of the CCOP is to provide state-of-the-art cancer care to patients and families as close to home as possible. This CCOP will progressively increase the number of patients accrued to NCI approved cancer treatment and control studies via an established relationship with NCCTG, ECOG, and CCSG. Individual aims of the research program include: expanding cancer control efforts, continuing high accrual to cancer treatment protocols, expanding the outreach and consultation service, computerization of the CCOP data base and enhancing the CCOP quality control program. The CCOP network includes St. Luke's Hospitals and the Fargo Clinic, 30 Meritcare regional centers, and two group physician practices. Geographically the network covers virtually all of North Dakota, Northwestern Minnesota and the Northeast corner of South Dakota. These institutions provide the most comprehensive cancer care program within a 200 mile radius. The estimated number of new cancer patients currently seen is approximately 1300 per year. To enhance the comprehensive cancer program and to accommodate the increased volume of patients seeking treatment, St. Luke's Hospitals and Fargo Clinic are building a new cancer center. The Roger Maris Cancer Center will house all of the outpatient services as well as the CCOP and research areas. Twenty-two hundred square feet of the 31,000 square foot complex will be devoted to CCOP and research activities.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
5U10CA037417-09
Application #
3558062
Study Section
Special Emphasis Panel (SRC (54))
Project Start
1983-09-30
Project End
1994-05-31
Budget Start
1992-06-20
Budget End
1993-05-31
Support Year
9
Fiscal Year
1992
Total Cost
Indirect Cost
Name
St. Luke's Hospitals-Meritcare
Department
Type
DUNS #
City
Fargo
State
ND
Country
United States
Zip Code
58103
Barton, Debra L; Sloan, Jeff A; Shuster, Lynne T et al. (2018) Evaluating the efficacy of vaginal dehydroepiandosterone for vaginal symptoms in postmenopausal cancer survivors: NCCTG N10C1 (Alliance). Support Care Cancer 26:643-650
Bhatia, Aarti K; Lee, Ju-Whei; Pinto, Harlan A et al. (2017) Double-blind, randomized phase 3 trial of low-dose 13-cis retinoic acid in the prevention of second primaries in head and neck cancer: Long-term follow-up of a trial of the Eastern Cooperative Oncology Group-ACRIN Cancer Research Group (C0590). Cancer 123:4653-4662
Schild, Steven E; Hillman, Shauna L; Tan, Angelina D et al. (2017) Long-Term Results of a Trial of Concurrent Chemotherapy and Escalating Doses of Radiation for Unresectable Non-Small Cell Lung Cancer: NCCTG N0028 (Alliance). J Thorac Oncol 12:697-703
Sio, Terence T; Atherton, Pamela J; Birckhead, Brandon J et al. (2016) Repeated measures analyses of dermatitis symptom evolution in breast cancer patients receiving radiotherapy in a phase 3 randomized trial of mometasone furoate vs placebo (N06C4 [alliance]). Support Care Cancer 24:3847-55
Neal, Joel W; Dahlberg, Suzanne E; Wakelee, Heather A et al. (2016) Erlotinib, cabozantinib, or erlotinib plus cabozantinib as second-line or third-line treatment of patients with EGFR wild-type advanced non-small-cell lung cancer (ECOG-ACRIN 1512): a randomised, controlled, open-label, multicentre, phase 2 trial. Lancet Oncol 17:1661-1671
Pachman, Deirdre R; Qin, Rui; Seisler, Drew et al. (2016) Comparison of oxaliplatin and paclitaxel-induced neuropathy (Alliance A151505). Support Care Cancer 24:5059-5068
Park, Haeseong; Qin, Rui; Smith, Thomas J et al. (2015) North Central Cancer Treatment Group N10C2 (Alliance): a double-blind placebo-controlled study of magnesium supplements to reduce menopausal hot flashes. Menopause 22:627-32
Dronca, Roxana S; Allred, Jacob B; Perez, Domingo G et al. (2014) Phase II study of temozolomide (TMZ) and everolimus (RAD001) therapy for metastatic melanoma: a North Central Cancer Treatment Group study, N0675. Am J Clin Oncol 37:369-76
Barton, Debra L; Thanarajasingam, Gita; Sloan, Jeff A et al. (2014) Phase III double-blind, placebo-controlled study of gabapentin for the prevention of delayed chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy, NCCTG N08C3 (Alliance). Cancer 120:3575-83
Province, M A; Goetz, M P; Brauch, H et al. (2014) CYP2D6 genotype and adjuvant tamoxifen: meta-analysis of heterogeneous study populations. Clin Pharmacol Ther 95:216-27

Showing the most recent 10 out of 136 publications